-
South America, Asia, and Europe.
BioMarin's core
business and
research is in
enzyme replacement therapies (ERTs).
BioMarin was the
first company to provide...
-
typical cost of
treating a
patient with
Kuvan is US$100,000 per year.
BioMarin holds the
patent for
Kuvan until at
least 2024, but Par Pharmaceutical...
- r-elliott-targets-drugmaker-
biomarin-sources-2023-11-07/ "Exclusive:
Activist investor Elliott targets drugmaker BioMarin -sources"]. Reuters. Retrieved...
- gene
therapy used for the
treatment of
hemophilia A. It was
developed by
BioMarin Pharmaceutical.
Valoctocogene roxaparvovec is made of a
virus (AAV5) that...
- is a
synthetic version of this enzyme.
Elosulfase alfa was
developed by
BioMarin Pharmaceutical Inc. and
approved for use in the US by the Food and Drug...
-
Approves BioMarin's Voxzogo (vosoritide) for the
Treatment of
Children with
Achondroplasia from Age 2
Until Growth Plates Close" (Press release).
BioMarin Pharmaceutical...
- from the
index on July 24 due to its
acquisition by AT&T and
replaced by
BioMarin Pharmaceutical on July 27. Sigma-Aldrich was
removed on July 31, after...
- salt form,
which was
developed through a
series of
companies ending with
BioMarin Pharmaceutical which obtained European approval in 2009
under the trade...
- Rare-Disease Portfolio".
BioMarin.
November 24, 2014.
Archived from the
original on
March 22, 2015. "FDA
Accepts BioMarin's NDA for Drisa****n". Parent...
- Naglazyme), a
recombinant enzyme replacement therapy also
produced by
Biomarin was
approved for MPS VI (Marateaux-Lamy syndrome). In July 2006, the United...
